Vitamin K2 and D3 Supplementation Does Not Reduce Cardiovascular Events
Based on the highest quality evidence from recent randomized controlled trials, vitamin K2 and D3 supplementation does not reduce cardiovascular events in generally healthy adults or those with existing coronary artery calcification. The most definitive data comes from the 2022 AVADEC trial published in Circulation, which showed no benefit on cardiovascular outcomes 1.
Evidence from Randomized Controlled Trials
The AVADEC trial (2022) enrolled 365 elderly men with significant aortic valve calcification (>300 AU) and randomized them to 720 μg/day vitamin K2 (MK-7) plus 25 μg/day vitamin D versus placebo for 24 months 1. The results were definitively negative:
- No reduction in coronary artery calcification progression (mean difference 17 AU, 95% CI -86 to 53, P=0.64)
- No difference in cardiovascular events (10 vs 10 patients, P=0.99)
- No difference in all-cause mortality (1 vs 4 patients, P=0.37)
- Vitamin K2 successfully reduced dp-ucMGP (a marker of vitamin K deficiency), confirming biological activity, yet this did not translate to clinical benefit
A 2023 substudy of the same trial specifically examined coronary artery disease progression in 304 men without prior ischemic heart disease 2. While the overall group showed no benefit (Δ203 vs Δ254 AU, P=0.089), a post-hoc subgroup analysis suggested possible benefit in those with CAC scores ≥400 AU (Δ288 vs Δ380 AU, P=0.047). However, this subgroup finding is hypothesis-generating only and cannot override the primary negative results.
Most recently, a 2025 substudy examined inflammation markers and found no effect on epicardial adipose tissue or systemic inflammatory markers despite confirmed vitamin K2 activity 3.
Guideline Recommendations
The 2016 joint guideline from the National Osteoporosis Foundation and American Society for Preventive Cardiology provides moderate-quality evidence (B level) that calcium with or without vitamin D has no relationship—beneficial or harmful—with cardiovascular disease risk 4. This guideline emphasizes that:
- Calcium intake up to 2000-2500 mg/day should be considered safe from a cardiovascular standpoint
- Discontinuation of supplements for cardiovascular safety concerns is not necessary
- No established biological mechanism supports an association between calcium/vitamin D and cardiovascular disease
The 2018 review in Circulation Research highlights critical limitations of vitamin D supplementation evidence 5:
- Observational studies showed associations, but randomized controlled trials failed to confirm cardiovascular benefit (except in chronic kidney disease patients with impaired 1-alpha-hydroxylase activity)
- The relationship between 25(OH)D3 levels and cardiovascular risk follows a U-shaped curve, with minimum risk at ~20 ng/mL—far below levels typically recommended
- One study of over 5000 patients found no reduction in cardiovascular mortality despite increasing 25(OH)D levels by 20 ng/mL
Observational Data Cannot Substitute for RCT Evidence
While a 2019 meta-analysis of observational studies suggested dietary vitamin K may reduce coronary heart disease risk (HR 0.92 for phylloquinone, HR 0.70 for menaquinone) 6, these associations are confounded by healthy lifestyle factors. The 2017 narrative review proposing synergistic benefits 7 relies on mechanistic reasoning rather than clinical outcomes data.
Clinical Recommendation
Do not recommend vitamin K2 and D3 supplementation specifically for cardiovascular event reduction. The evidence is clear:
- For generally healthy adults: No cardiovascular benefit demonstrated in RCTs
- For patients with coronary calcification: The AVADEC trial definitively showed no benefit
- For bone health: Supplementation remains appropriate when dietary intake is inadequate, and this can be safely continued without cardiovascular concerns
Important Caveats
- Chronic kidney disease patients represent a distinct population where vitamin D-hormone supplementation may improve vascular function due to impaired renal 1-alpha-hydroxylase activity 5
- The subgroup with CAC ≥400 AU showing possible benefit 2 requires validation in prospective trials before changing practice
- Vitamin D supplementation for non-cardiovascular indications (bone health, immune function) remains appropriate and carries no cardiovascular harm 4
What This Means for Practice
If patients are taking vitamin K2 and D3 for bone health or other indications, do not discontinue for cardiovascular safety concerns—the supplements are safe 4. However, do not initiate or continue these supplements with the expectation of preventing heart attacks, strokes, or cardiovascular death. The biological activity (reduced dp-ucMGP) does not translate to clinical benefit in cardiovascular outcomes 1.